Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 13/20 | 0.65 |
| ▸ | RORC | P51449 | 2/20 | 0.35 |
| ▸ | CBLB | Q13191 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24529269 | 1.00 | HCRTR2 (0.65) | HCRTR2RORCCBLBOPRK1TGFBR1 | |
| SCHEMBL27180875 | 1.00 | HCRTR2 (0.65) | HCRTR2RORCCBLBOPRK1TGFBR1 | |
| SCHEMBL29723498 | 1.00 | HCRTR2 (0.65) | HCRTR2RORCCBLBOPRK1TGFBR1 | |
| SCHEMBL24529299 | 0.92 | HCRTR2 (0.66) | HCRTR2RORCCBLBOPRK1RET | |
| SCHEMBL27181350 | 0.92 | HCRTR2 (0.66) | HCRTR2RORCCBLBOPRK1RET | |
| SCHEMBL27180820 | 0.90 | HCRTR2 (0.63) | HCRTR2 | |
| SCHEMBL24529580 | 0.90 | HCRTR2 (0.63) | HCRTR2 | |
| SCHEMBL27180818 | 0.90 | HCRTR2 (0.63) | HCRTR2 | |
| SCHEMBL24529442 | 0.88 | HCRTR2 (0.62) | HCRTR2RORCOPRK1 | |
| SCHEMBL27181215 | 0.88 | HCRTR2 (0.62) | HCRTR2RORCOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | claimed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | claimed |
| EP-4262788-B1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101555-A1 | UREA OREXIN RECEPTOR AGONISTS | HCRTR1, HCRTR2, UTS2R | HCRTR2 2/4885RORC 556/4885CBLB 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.